Cholecystokinin Acts as an Essential Factor in the Exacerbation of Pancreatic Bile Duct Ligation-Induced Rat Pancreatitis Model Under Non-fasting Condition
スポンサーリンク
概要
- 論文の詳細を見る
We examined the influence of 2 gut hormones involved in the enhancement of pancreatic exocrine secretion, secretin and cholecystokinin(CCK), in the exacerbation of pancreatitis.We also examined the role of the vagal system, which was considered to be a transmission route for these hormones.Our model of pancreatitis in the rat was prepared by pancreatic bile duct ligation(PBDL), which simultaneously ligated the pancreatic duct and the common bile duct.Serum amylase activity and histopathological changes in the pancreas were used as indices of pancreatitis.We also measured the volume of pancreatic juice, as well as the amylase activity and protein level of the pancreatic juice, as indices of increased pancreatic exocrine secretion.Two gut hormones were given 6 times at 1−h intervals.Administration of secretin(1−3 μg/kg, s.c.)did not influence serum amylase activity in rats with PBDL−induced pancreatitis.However, food stimulation and administration of CCK−8(1 μg/kg, s.c.)increased serum amylase activity and promoted vacuolation of the pancreatic acinar cells in rats with PBDL−induced pancreatitis.Administration of atropine(3 mg/kg, s.c.)or a CCK1−receptor antagonist, Z−203(0.1 mg/kg, i.v.), inhibited food−stimulated or CCK−8−induced(1 μg/kg, s.c.)enhancement of pancreatic exocrine secretion and exacerbation after the development of PBDL−induced pancreatitis.These results suggest that not secretin, which regulates the volume of pancreatic juice, but CCK, which regulates the secretion of pancreatic enzymes via the vagal system, plays an essential role in food−stimulated exacerbation after the development of pancreatitis.
- 社団法人 日本薬理学会の論文
- 2000-09-01
著者
-
Yoshinaga Koji
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd.
-
Yoshinaga Koji
Central Res. Laboratories Zeria Pharmaceutical Co. Ltd.
-
Yoshinaga Koji
Central Research Laboratories Zeria Pharmaceutical Co. Ltd
-
SEGAWA Yoshihide
Zeria Pharmaceutical Co., Ltd.
-
Segawa Y
Zeria Pharmaceutical Co. Ltd.
-
WASHIZUKA Masataka
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd
-
SEGAWA Yoshihide
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd
-
Washizuka Masataka
Central Research Laboratories Zeria Pharmaceutical Co. Ltd
関連論文
- Pharmacological Evaluation of Analgesic Effects of the Cholecystokinin2 Receptor Antagonist Z-360 in Mouse Models of Formalin- and Cancer-Induced Pain
- Z-100, an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, Augments Anti-tumor Activities of X-Ray Irradiation against B16 Melanoma in Association with the Improvement of Type 1T Cell Responses(Miscellaneous)
- Antimetastatic Effect of an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, Z-100, through the Production of Interleukin-12(Miscellaneous)
- Anti-Tumor Mechanism of Z-100, an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, on Pulmonary Metastases of B16F10 Melanoma : Restoration of Helper T Cell Responses via Suppression of Glucocorticoid-Genesis
- Z-360, a Novel Cholecystokinin-2/Gastrin Receptor Antagonist, Inhibits Gemcitabine-Induced Expression of the Vascular Endothelial Growth Factor Gene in Human Pancreatic Cancer Cells
- Possible Changes in Expression of Chemotaxin LECT2 mRNA in Mouse Liver after Concanavalin A-Induced Hepatic Injury
- D-Galactosamine-Induced Mouse Hepatic Apoptosis : Possible Involvement with Tumor Necrosis Factor, but not with Caspase-3-Activity
- Fasting Exacerbates Acute Pancreatitis by Occlusion of the Common Bile Duct in Rats
- Diet Stimulation as a Synergistic Factor of Aggravation in a Pancreatic Bile Duct Ligation-Induced Rat Pancreatitis Model
- Cholecystokinin Acts as an Essential Factor in the Exacerbation of Pancreatic Bile Duct Ligation-Induced Rat Pancreatitis Model Under Non-fasting Condition